Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ZS -16.6%, ASND -16% (enters into $150 mln funding agreement with Royalty Pharma), PD -14.2%, ASAN -13.2% (also names new CFO), REVG -12.9%, DLTR -12.6%, HRL -5.2%, GPK -1.7% (guidance), OS -0.7%
Other news:
- ATHA -73.3% (topline results from Phase 2/3 LIFT-AD clinical trial of fosgonimeton)
- STWD -3.9% (prices offering of 17.5 mln shares of common stock for gross proceeds of ~$345.1 million)
- IRT -3.8% (prices offering of 10.0 mln shares of common stock at $19.75 per share)
- CIFR -3.4% (files mixed shelf; reports August operations)
- ARCB -2.9% (provides prelim August metrics)
- ULS -2.2% (stock offering)
- AKBA -2.1% ($250 mln mixed shelf offering)
- NVDA -1.9% (receives DOJ subpoena, according to Bloomberg)
- STC -1.9% (increases dividend)
- PACS -1.4% (stock offering)
- VFC -1.2% (discloses the availability of supplemental investor information; Excluding the impact from Supreme in fiscal 2025, there are no changes to VFC's expectations for Q2'FY25)
- RNG -1.1% (CFO resigns)
- PCVX -1% ($1.0 bln stock offering and pre-funded warrants)